

Michael Mian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396994/publications.pdf>

Version: 2024-02-01

84
papers

1,781
citations

236612

25
h-index

301761

39
g-index

85
all docs

85
docs citations

85
times ranked

3001
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
2	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910.	0.8	99
3	Comparison of Complications in Three Incontinent Urinary Diversions. <i>European Urology</i> , 2008, 54, 825-834.	0.9	73
4	Pim kinases in hematological malignancies: where are we now and where are we going?. <i>Journal of Hematology and Oncology</i> , 2014, 7, 95.	6.9	72
5	Genome wide DNA profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255.	1.2	70
6	Fluorescence In Situ Hybridisation in the Diagnosis of Upper Urinary Tract Tumours. <i>European Urology</i> , 2010, 58, 288-292.	0.9	68
7	Single nucleotide polymorphism arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 149, 569-577.	1.2	53
8	Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. <i>Nutrition and Cancer</i> , 2015, 67, 12-26.	0.9	53
9	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
10	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP 21. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
11	Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011, 155, 274-277.	1.2	47
12	Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67.	0.8	46
13	Four Years Experience in Bladder Preserving Management for Muscle Invasive Bladder Cancer. <i>European Urology</i> , 2005, 47, 773-779.	0.9	42
14	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	1.2	40
15	Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. <i>Hematological Oncology</i> , 2019, 37, 333-344.	0.8	38
16	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231.	0.8	36
17	Patterns of survival of follicular lymphomas at a single institution through three decades. <i>Leukemia and Lymphoma</i> , 2010, 51, 1028-1034.	0.6	33
18	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33

#	ARTICLE	IF	CITATIONS
19	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. <i>Oncotarget</i> , 2016, 7, 7597-7609.	0.8	31
20	Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. <i>World Journal of Urology</i> , 2014, 32, 1219-1223.	1.2	30
21	Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. <i>Oncotarget</i> , 2017, 8, 20394-20409.	0.8	30
22	Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1683-1685.	0.6	29
23	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
24	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
25	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
26	Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. <i>Journal of Clinical Pathology</i> , 2006, 59, 984-987.	1.0	27
27	Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells. <i>Pathobiology</i> , 2010, 77, 129-135.	1.9	26
28	Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. <i>Urologia Internationalis</i> , 2015, 94, 25-30.	0.6	25
29	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	0.8	25
30	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
31	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
32	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
33	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	0.8	20
34	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
35	Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. <i>Annals of Hematology</i> , 2014, 93, 267-277.	0.8	17
36	Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering. <i>Clinical Lung Cancer</i> , 2015, 16, 305-312.	1.1	17

#	ARTICLE	IF	CITATIONS
37	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
38	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013, 88, 955-960.	2.0	14
39	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013, 24, 1378-1384.	0.6	13
40	Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2006, 108, 3045-3045.	0.6	13
41	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
42	Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. <i>SpringerPlus</i> , 2014, 3, 123.	1.2	12
43	R-CHOP versus R-COMP: Are They Really Equally Effective?. <i>Clinical Oncology</i> , 2014, 26, 648-652.	0.6	12
44	B Cell Lymphoma with Lung Involvement: What Is It about?. <i>Acta Haematologica</i> , 2015, 133, 221-225.	0.7	11
45	Docetaxel in the treatment of non-small cell lung cancer (NSCLC) – an observational study focusing on symptom improvement. <i>Anticancer Research</i> , 2013, 33, 3831-6.	0.5	10
46	Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?. <i>Anticancer Research</i> , 2014, 34, 6701-4.	0.5	10
47	Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2013, 92, 121-123.	0.8	9
48	Primary central nervous system lymphoma: Novel precision therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 139-145.	2.0	9
49	STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. <i>Hematological Oncology</i> , 2020, 38, 106-110.	0.8	9
50	Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7. <i>Prostate</i> , 2006, 66, 966-970.	1.2	8
51	Osteolytic bone lesions as a rare sign of progression of chronic lymphocytic leukemia without evidence of Richter syndrome. <i>Leukemia and Lymphoma</i> , 2012, 53, 993-995.	0.6	8
52	Idiopathic Bence-Jones proteinuria: a new characterization of an old entity. <i>Annals of Hematology</i> , 2013, 92, 1263-1270.	0.8	7
53	Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e489-e495.	0.2	7
54	Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. <i>Experimental Hematology and Oncology</i> , 2015, 5, 1.	2.0	6

#	ARTICLE	IF	CITATIONS
55	Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. <i>Annals of Hematology</i> , 2015, 94, 593-601.	0.8	6
56	90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 82-88.	0.2	6
57	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	2.0	6
58	A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 2559-64.	0.5	6
59	90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. <i>Anticancer Research</i> , 2014, 34, 5121-5.	0.5	6
60	Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?. <i>Anticancer Research</i> , 2016, 36, 1059-65.	0.5	6
61	Phase III trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. <i>British Journal of Haematology</i> , 2019, 185, 944-947.	1.2	5
62	Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , 2006, 47, 940-943.	0.6	4
63	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	0.6	4
64	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010, 34, e243-e245.	0.4	3
65	Single- vs. Two-Stage Fowler-Stephens Orchidopexy: Are Two Operations Better than One? A Retrospective, Single-Institution Critical Analysis. <i>Current Urology</i> , 2011, 5, 12-17.	0.4	3
66	Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. <i>SpringerPlus</i> , 2014, 3, 342.	1.2	3
67	Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?. <i>Acta Oncologica</i> , 2015, 54, 953-955.	0.8	3
68	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005.	1.0	3
69	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
70	Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2007, 110, 1282-1282.	0.6	3
71	Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. <i>World Journal of Urology</i> , 2013, 31, 293-297.	1.2	1
72	Quality of life in patients with invasive bladder cancer who cannot undergo cystectomy. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 339-345.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , 2010, 116, 1784-1784.	0.6	1
74	Authors' response to Professor J. F. Seymour. <i>Leukemia and Lymphoma</i> , 2012, 53, 1012-1012.	0.6	0
75	Rituximab: how evidence based medicine can change our clinical practice. <i>Leukemia and Lymphoma</i> , 2014, 55, 1694-1696.	0.6	0
76	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
77	Changing treatment paradigms in lymphoma: new targets and new drugs. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 184-188.	0.3	0
78	Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults. <i>The Cochrane Library</i> , 0, , .	1.5	0
79	Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 2744-2744.	0.6	0
80	Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.. <i>Blood</i> , 2006, 108, 5380-5380.	0.6	0
81	240: Is Fish on Voided Urine a Predictive Marker for the Response to Farmorubicin Intravesical Instillation in Intermediate Risk Bladder Cancer?. <i>Journal of Urology</i> , 2007, 177, 80-80.	0.2	0
82	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3432-3432.	0.6	0
83	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008, 112, 3608-3608.	0.6	0
84	Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). <i>Hematological Oncology</i> , 2022, 40, 609-616.	0.8	0